Partin Tables update 2007: Organ confined disease
Data for the original Partin tables were collected from men treated from 1982 to 1991. A multi-institutional update was performed 4 years later, based on data from 1982 to 1996. A further update accounting for continuing stage migration was made in 2001, examining patients from 1994 to 2000. This model has been validated in various clinical settings, from academic medical centers in the United States, Canada, and Turkey to cohorts of community patients.
Research authors: Danil V. Makarov, Bruce J. Trock, Elizabeth B. Humphreys, Leslie A. Mangold, Patrick C. Walsh, Jonathan I. Epstein, Alan W. Partin
Details Formula Study characteristics Files & References
★★★
Model author
Model ID
744
Version
1.5
Revision date
2018-03-12
Specialty
MeSH terms
  • Partin Tables
  • Prostate Cancer
  • Prostate Specific Antigen
  • Gleason Score
  • Model type
    R-Script model (Calculation)
    Status
    public
    Rating
    Share
    Formula
    No Formula defined yet
    Condition Formula

    Additional information

    Men enrolled in this cohort had (a) preoperative monoclonal serum PSA level assessed on an ambulatory basis before RP, either before or at least 4 weeks after prostate biopsy, (b) biopsy histologic grade (GS) determined at our institution, and (c) clinical stage assigned by the attending physician (American Joint Committee on Cancer TNM staging system, 1992/2002) of T1c or T2a/b/c. Men were excluded because they lacked this information (n = 29) or received preoperative neoadjuvant hormonal therapy (107). Men were also excluded for preoperative treatment with 5-alpha reductase inhibitors (71), chemo-therapy (5), or androgenic/estrogenic herbal therapies (1) because of potential influence on PSA. Men with pathologic diagnoses other than adenocarcinoma of the prostate (7), absence of cancer on pathology (4), or missing pathologic information (33) (including 30 men with tumor extending to an inked surgical margin, unevaluable for OC versus extraprostatic extension [EPE]) were excluded. One man
    with biopsy GS 2 + 2 = 4 was excluded,19 leaving a cohort of 5730 patients.

    Study Population

    Total population size: 5730
    Males: {{ model.numberOfMales }}
    Females: {{ model.numberOfFemales }}

    Continuous characteristics

    Name Mean SD Unit
    Age 57.4 6.4 years

    Categorical characteristics

    Name Subset / Group Nr. of patients
    Race White 5081
    African american 372
    Hispanic 56
    Asian 58
    Other 158
    PSA Groups (ng/ml) 0-2.5 452
    2.6-4.0 946
    4.1-6.0 1994
    6.1-8.0 1093
    8.1-10.0 578
    >10.0 667
    Biopsy gleason score 5-6 4402
    3 + 4 = 7 816
    4 + 3 = 7 348
    ≥8 164
    Clinical stage (AJCC-TNM 2002) T1c 4419
    T2a 998
    T2b 279
    T2c 34
    Prostatectomy gleason score 5-6 3693
    3 + 4 1304
    4 + 3 425
    8-10 308
    Cancer state Organ confined 4204
    Extraprostatic Extension (SV-, LN-) 1276
    Seminal Vesicle involvement (LN-) 180
    Lymph node involvement 70
    Partin Tables update 2007: Organ confined disease
    V-1.5-744.18.03.12
    Refer to Intended Use for instructions before use
    Evidencio B.V., Irenesingel 19, 7481 GJ, Haaksbergen, the Netherlands

    Related files

    Calculated risk for organ confined disease is:
    ...
    %

    {{ resultSubheader }}

    {{ model.survival.PITTitle }}

    {{ model.survival.YNETitle }}

    Result
    Note
    Notes are only visible in the result download and will not be saved by Evidencio

    Calculated risk for organ confined disease is: %

    {{ resultSubheader }}
    {{ chart.title }}

    Outcome stratification

    Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

    Conditional information

    Result interpretation

    Knowing the chance of organ confined disease in prostate cancer patients might help the clinician to make a decision regarding best possible treatment. 

    Confidence intervals of the calculated chances can be found in the table below. 

     

    {{ file.classification }}

    Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

    Comments
    Rating
    Comment
    Please enter a comment of rating
    Comments are visible to anyone

    Model feedback

    No feedback yet 1 Comment {{ model.comments.length }} Comments
    Not rated | On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
    logo

    Please sign in to enable Evidencio print features

    In order to use the Evidencio print features, you need to be logged in.
    If you don't have an Evidencio Community Account you can create your free personal account at:

    https://www.evidencio.com/registration

    Printed results - Examples {{ new Date().toLocaleString() }}


    Evidencio Community Account Benefits


    With an Evidencio Community account you can:

    • Create and publish your own prediction models.
    • Share your prediction models with your colleagues, research group, organization or the world.
    • Review and provide feedback on models that have been shared with you.
    • Validate your models and validate models from other users.
    • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
    • Use and save prediction models and their data.
    • Use patient specific protocols and guidelines based on sequential models and decision trees.
    • Stay up-to-date with new models in your field as they are published.
    • Create your own lists of favorite models and topics.
    A personal Evidencio account is free, with no strings attached! Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.

    Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.